Gemphire Therapeutics Inc (GEMP) Expected to Announce Earnings of -$0.39 Per Share

Wall Street analysts forecast that Gemphire Therapeutics Inc (NASDAQ:GEMP) will announce earnings per share of ($0.39) for the current quarter, Zacks reports. Zero analysts have made estimates for Gemphire Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.37) and the lowest estimate coming in at ($0.41). Gemphire Therapeutics reported earnings of ($0.63) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 38.1%. The firm is scheduled to issue its next earnings results on Thursday, March 21st.

On average, analysts expect that Gemphire Therapeutics will report full-year earnings of ($1.89) per share for the current financial year, with EPS estimates ranging from ($1.89) to ($1.88). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.05) per share, with EPS estimates ranging from ($2.50) to ($1.59). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Gemphire Therapeutics.

Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.04.

A number of analysts have weighed in on the company. Raymond James lowered Gemphire Therapeutics from an “outperform” rating to a “market perform” rating and set a $22.00 target price on the stock. in a research note on Tuesday, August 7th. Zacks Investment Research lowered Gemphire Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 10th. Jefferies Financial Group lowered Gemphire Therapeutics from a “buy” rating to a “hold” rating and set a $15.00 target price on the stock. in a research note on Monday, August 13th. Roth Capital reiterated a “neutral” rating and issued a $30.00 target price on shares of Gemphire Therapeutics in a research note on Friday, August 10th. Finally, Canaccord Genuity reissued a “buy” rating and set a $6.00 price target on shares of Gemphire Therapeutics in a research report on Monday, August 13th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $17.13.

NASDAQ:GEMP opened at $1.17 on Friday. Gemphire Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $11.43. The firm has a market cap of $16.69 million, a P/E ratio of -0.36 and a beta of 2.46. The company has a debt-to-equity ratio of 0.59, a quick ratio of 3.27 and a current ratio of 3.27.

A number of hedge funds and other institutional investors have recently modified their holdings of GEMP. VHCP Management III LLC purchased a new position in shares of Gemphire Therapeutics in the third quarter worth about $1,791,000. BlackRock Inc. increased its position in shares of Gemphire Therapeutics by 2,210.5% in the third quarter. BlackRock Inc. now owns 675,038 shares of the company’s stock valued at $1,391,000 after buying an additional 645,822 shares in the last quarter. VHCP Management II LLC purchased a new stake in shares of Gemphire Therapeutics in the third quarter valued at approximately $1,058,000. Millennium Management LLC purchased a new stake in shares of Gemphire Therapeutics in the second quarter valued at approximately $1,981,000. Finally, Nomura Holdings Inc. purchased a new stake in shares of Gemphire Therapeutics in the second quarter valued at approximately $556,000. 29.20% of the stock is owned by institutional investors and hedge funds.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.

Featured Article: Liquidity

Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit